The Tampa Hillsborough EDC has attracted some of the brightest business leaders in the Tampa and Hillsborough County community. Each year, new executive officers are elected to help lead the organization on yet another successful year.
Our 2019 Executive Officers are:
Judy Genshaft, Ph.D.
President, University of South Florida
Since becoming president in 2000, Dr. Judy Genshaft has catapulted the University of South Florida System to national and international prominence for student success, academic rigor, research and innovation, and economic development. USF recently was given the elite designation of “Preeminent State Research University,” becoming only the third Florida institution to earn this prestigious honor. USF was also recently accepted into the distinguished Phi Beta Kappa honor society, a sign of the institution’s growing national reputation.
With campuses in Tampa, St. Petersburg and Sarasota-Manatee, the USF System serves 50,500 students in 235 degree programs ranging from undergraduate to doctor of medicine and several other health professions. More than 13,000 students earn degrees each year at USF’s three separately accredited institutions.
President Genshaft has been instrumental in economic development efforts in the Tampa Bay region. In addition to serving at the Tampa Hillsborough Economic Development Corporation’s Chair for 2019, she has served as chair of The Greater Tampa Chamber of Commerce, the Tampa Bay Partnership, and the Greater Tampa Chamber of Commerce Committee of 100. The university has been a catalyst for economic development; USF Tampa’s innovation and economic development efforts alone generate more than $400 million in statewide impact each year, sustain more than 3,000 jobs, and return more than $52 million in tax revenue to local, state and federal governments
Managing Director, Depository Trust and Clearing Corporation
Marie Chinnici-Everitt is Managing Director and Chief Marketing Officer with responsibility for DTCC’s global marketing and corporate communications functions, including overseeing the firm’s global corporate image and positioning, business marketing, and branding initiatives, as well as internal and external communications for DTCC, its subsidiaries, and their respective business lines.
She is a member of DTCC’s Operating Committee and serves as Vice Chair of DTCC’s Diversity & Inclusion Council. Additionally, she serves as head of DTCC’s Tampa office, where she oversees the day-to-day operations of the site across all businesses and support functions. Chinnici-Everitt sits on the Board of the Tampa Hillsborough Economic Development Corporation and represents DTCC at the Tampa Bay Partnership.
She has over 25 years of marketing and communications experience in the financial services industry. Prior to DTCC, Chinnici-Everitt served as managing director and head of international business planning and enterprise events at Bank of America Merrill Lynch, where she led international business planning across all marketing and corporate affairs disciplines in Europe, Latin America, and Asia.
Tampa City President, Fifth Third Bank
James (Jim) Weiss serves as city president for Tampa, Florida, and senior commercial banking executive for Fifth Third Bank (North Florida), managing the Commercial Bank that comprises the middle market, government and institutional, healthcare, commercial real estate and treasury management departments in the Tampa Bay, Central Florida and Jacksonville markets.
He has over 20 years of commercial management experience, having previously served as commercial sales manager for Fifth Third Bank in St. Louis. Before coming to Fifth Third, Jim served as first vice president, middle market team lead for Commerce Bank N.A. in St. Louis.
Jim earned a Bachelor of Arts degree in mathematics with a minor in finance from Saint Louis University, from which he also received certification in economic development.
Immediate Past Chair
Dr. Alan List
President and CEO, Moffitt Cancer Center
Dr. Alan F. List is the President and CEO of Moffitt Cancer Center. He is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.
Prior to his current position, List served as Executive Vice President and Physician-in-Chief, the Vice Deputy Physician-in-Chief and the Chief of the Malignant Hematology Division at Moffitt, where he also holds the Morsani Endowed Chair.